Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities.

Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE

Publication: 2010- : New York : Springer Science+Business Media
Original Publication: New York, NY : Humana Press

Stomach Neoplasms*/therapy ; Cancer Survivors*/statistics & numerical data ; Survivorship* ; Quality of Life*; Humans ; Combined Modality Therapy/methods ; Patient Care Team

Purpose: Gastric cancer is the 5th most common malignancy worldwide. As early detection increases and treatments for gastric cancer improve, the number of gastric cancer survivors grows.
Methods: Here, we review the diagnosis and management of gastric cancer and discuss important considerations for gastric cancer survivorship including cancer surveillance, weight loss, malnutrition, fatigue, specific complications related to surgery and radiation, quality of life in gastric cancer survivorship, health behavior, and models of survivorship.
Results: Multimodality therapy with chemotherapy and surgery can result in chronic toxicities in multiple organ systems. This emphasizes the need for a multidisciplinary survivorship care model including cancer surveillance, management of chronic toxicities, and optimization of modifiable risk factors with long-term involvement of appropriate providers.
Conclusion: Adequately caring for gastric cancer survivors requires a coordinated, multidisciplinary approach.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine. 2022;47: 101404. (PMID: 35497064904610810.1016/j.eclinm.2022.101404)
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. (PMID: 3353833810.3322/caac.21660)
Global health estimates: leading causes of death, https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death . Accessed on 30 Nov 2023.
Zhao J-K, Wu M, Kim CH, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province. China Eur J Cancer Prev. 2017;26:357–64. (PMID: 2727573510.1097/CEJ.0000000000000262)
Stomach Cancer — Cancer Stat Facts, https://seer.cancer.gov/statfacts/html/stomach.html . Accessed 30 October 2023.
Nicole McMillian N, Lenora Pluchino MA, Ajani JA, et al. NCCN Guidelines Version 1.2023 Gastric Cancer Continue NCCN Guidelines Panel Disclosures, https://www.nccn.org/home/member - (2023).
Zhu H, Yang X, Zhang C, et al. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS ONE. 2013;8: e70955. (PMID: 23967140374388410.1371/journal.pone.0070955)
D’Elia L, Galletti F, Strazzullo P. Dietary salt intake and risk of gastric cancer. 2014, pp. 83–95.
Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015;16:1599–600. (PMID: 2651494710.1016/S1470-2045(15)00444-1)
Lee T-Y, Chiang E-P, Shih Y-T, et al. Lower serum folate is associated with development and invasiveness of gastric cancer. World J Gastroenterol. 2014;20:11313–20. (PMID: 25170216414577010.3748/wjg.v20.i32.11313)
Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer–viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8. (PMID: 27557308675486110.1056/NEJMsr1606602)
Wang P-L, Xiao F-T, Gong B-C, et al. Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8:99013–23. (PMID: 29228746571678610.18632/oncotarget.20918)
Gupta S, Tao L, Murphy JD, et al. Race/ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology. 2019;156:59-62.e4. (PMID: 3026771310.1053/j.gastro.2018.09.045)
Tavakoli A, Monavari SH, Solaymani Mohammadi F, et al. Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:493. (PMID: 32487043726838710.1186/s12885-020-07013-x)
Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors. Ann Intern Med. 2012;156:757. (PMID: 22665813355425410.7326/0003-4819-156-11-201206050-00002)
Takeno S, Hashimoto T, Maki K, et al. Gastric cancer arising from the remnant stomach after distal gastrectomy: a review. World J Gastroenterol. 2014;20:13734–40. (PMID: 25320511419455710.3748/wjg.v20.i38.13734)
Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol. 2010;172:1280–5. (PMID: 2093763210.1093/aje/kwq299)
Dikken JL, van de Velde CJH, Coit DG, et al. Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012;5:49–69. (PMID: 22282708326397910.1177/1756283X11410771)
Kim TH, Kim IH, Kang SJ, et al. Korean Practice Guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer. 2023;23:3. (PMID: 36750993991161910.5230/jgc.2023.23.e11)
Ahmad SA, Xia BT, Bailey CE, et al. An update on gastric cancer. Curr Probl Surg. 2016;53:449–90. (PMID: 2767191110.1067/j.cpsurg.2016.08.001)
Mukkamalla SKR, Recio-Boiles A, Babiker HM. Gastric Cancer. 2023.
Hejna M, Wöll E, Tschandl P, et al. Cutaneous paraneoplastic disorders in stomach cancer: collaboration between oncologically active dermatologists and clinical oncologists. Crit Rev Oncol Hematol. 2016;103:78–85. (PMID: 2724711710.1016/j.critrevonc.2016.04.013)
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79. (PMID: 33592120992792710.3322/caac.21657)
Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1–12. (PMID: 2356398610.1007/s10120-013-0252-z)
Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656–62. (PMID: 2268917910.1093/annonc/mds104)
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2023;401:1655–68.
Shitara K, Xu R-H, Moran DM, et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). 2023;41:4035–35. https://doi.org/10.1200/JCO20234116_suppl4035 .
Xiang Y-Y, Deng C-C, Liu H-Y, et al. The prognostic effect of multidisciplinary team intervention in patients with advanced gastric cancer. Curr Oncol. 2022;29:1201–12. (PMID: 35200601887124710.3390/curroncol29020102)
Ju M, Wang SC, Syed S, et al. Multidisciplinary teams improve gastric cancer treatment efficiency at a large safety net hospital. Ann Surg Oncol. 2020;27:645–50. (PMID: 3167710810.1245/s10434-019-08037-9)
Editors | Harrison’s principles of internal medicine, 20e | AccessMedicine | McGraw Hill Medical, https://accessmedicine.mhmedical.com/content.aspx?bookid=2129§ionid=191734545 . Accessed on 8 Oct 2023.
Cardoso R, Coburn NG, Seevaratnam R, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15:164–7. (PMID: 10.1007/s10120-012-0142-9)
Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2016;27:v38–49. (PMID: 2766426010.1093/annonc/mdw350)
Forbes N, Elhanafi SE, Al-Haddad MA, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. Gastrointest Endosc. 2023;98:271–84. (PMID: 3749826610.1016/j.gie.2023.03.015)
Group DGCS, Sasako M. Risk factors for surgical treatment in the Dutch gastric cancer trial. Br J Surg. 2005;84:1567–71.
Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆ Epub ahead of print 2021.  https://doi.org/10.1016/j.annonc.2020.11.017 .
Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:616–28. (PMID: 2965036310.1016/S1470-2045(18)30132-3)
Degiuli M, Reddavid R, Tomatis M, et al. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. Eur J Cancer. 2021;150:10–22. (PMID: 3388751410.1016/j.ejca.2021.03.031)
Nunobe S, Ida S. Current status of proximal gastrectomy for gastric and esophagogastric junctional cancer: a review. Ann Gastroenterol Surg. 2020;4:498–504. (PMID: 33005844751155810.1002/ags3.12365)
Elimova E, Janjigian YY, Mulcahy M, et al. It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma. J Clin Oncol. 2017;35:475–7. (PMID: 2812951910.1200/JCO.2016.69.7276)
Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet. 2019;393:1948–57. (PMID: 10.1016/S0140-6736(18)32557-1)
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376:687–97. (PMID: 10.1016/S0140-6736(10)61121-X)
Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30. (PMID: 3246918210.1056/NEJMoa2004413)
Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727–30. (PMID: 34912120895947010.1038/s41586-021-04161-3)
Shin C-H, Lee W-Y, Hong S-W, et al. Characteristics of gastric cancer recurrence five or more years after curative gastrectomy. Chin J Cancer Res. 2016;28:503–10. (PMID: 27877009510122410.21147/j.issn.1000-9604.2016.05.05)
Jin LX, Moses LE, Squires MH, et al. Factors associated with recurrence and survival in lymph node–negative gastric adenocarcinoma. Ann Surg. 2015;262:999–1005. (PMID: 2560776010.1097/SLA.0000000000001084)
Wang HM, Huang CM, Zheng CH, et al. Tumor size as a prognostic factor in patients with advanced gastric cancer in the lower third of the stomach. World J Gastroenterol. 2012;18:5470–5. (PMID: 23082065347111710.3748/wjg.v18.i38.5470)
Deng J, Zhang R, Pan Y, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Ann Surg Oncol. 2015;22:565–72. (PMID: 2515540010.1245/s10434-014-4014-x)
Zhou L, Li W, Cai S, et al. Large tumor size is a poor prognostic factor of gastric cancer with signet ring cell: results from the surveillance, epidemiology, and end results database. Medicine. 2019;98. Epub ahead of print 1 October 2019. https://doi.org/10.1097/MD.0000000000017367 .
Hill A, Kiss N, Hodgson B, et al. Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients. Epub ahead of print 2011. https://doi.org/10.1016/j.clnu.2010.07.015 .
Fukuda Y, Yamamoto K, Hirao M, et al. Prevalence of malnutrition among gastric cancer patients undergoing gastrectomy and optimal preoperative nutritional support for preventing surgical site infections. https://doi.org/10.1245/s10434-015-4820-9 .
Anderson B, Switzer NJ, Almamar A, et al. The impact of laparoscopic sleeve gastrectomy on plasma ghrelin levels: a systematic review. https://doi.org/10.1007/s11695-013-0999-7 .
Tanabe K, Takahashi M, Urushihara T, et al. Predictive factors for body weight loss and its impact on quality of life following gastrectomy. World J Gastroenterol. 2017;23:4823–30. (PMID: 28765704551464810.3748/wjg.v23.i26.4823)
Davis JL, Selby LV, Chou JF, et al. Patterns and predictors of weight loss after gastrectomy for cancer. Oncol. 2016;23:1639–45.
Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30:3687–96. (PMID: 2300832010.1200/JCO.2012.41.7238)
Hwang IC, Yun YH, Kim YW, et al. Factors related to clinically relevant fatigue in disease-free stomach cancer survivors and expectation-outcome consistency. Support Care Cancer. 2014;22:1453–60. (PMID: 2440241410.1007/s00520-013-2110-2)
Kobayashi D, Kodera Y, Fujiwara M, et al. Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. World J Surg. 2011;35:357–64. (PMID: 2110425010.1007/s00268-010-0860-2)
Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer. 1996;4:82–96. (PMID: 867335610.1007/BF01845757)
Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individuals. Am J Hosp Palliat Med. 2014;31:562–75. (PMID: 10.1177/1049909113494748)
Al Maqbali M, Al Sinani M, Al Naamani Z, et al. Prevalence of fatigue in patients with cancer: a systematic review and meta-analysis. J Pain Symptom Manage. 2021;61:167-189.e14. (PMID: 3276855210.1016/j.jpainsymman.2020.07.037)
Jankowski C, Carpenter KM, θ V-C, et al. NCCN Guidelines Version 1.2024 Cancer-Related Fatigue NCCN Guidelines Panel Disclosures Continue. 2023. https://www.nccn.org/home/member .
Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. 2020;145: 102837. (PMID: 3183066310.1016/j.critrevonc.2019.102837)
Dwyer, Mary. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ^® ) hematopoietic growth factors. 2023. https://www.nccn.org/home/member .
Pachman DR, Price KA, Carey EC. Nonpharmacologic approach to fatigue in patients with cancer. Cancer Journal (United States). 2014;20:313–8.
Hong Y, Wu C, Wu B. Effects of resistance exercise on symptoms, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy. Integr Cancer Ther. 2020;19. Epub ahead of print 10 September 2020. https://doi.org/10.1177/1534735420954912/ASSET/IMAGES/LARGE/10.1177_1534735420954912-FIG1.JPEG .
Singh B, Spence RR, Steele ML, et al. A systematic review and meta-analysis of the safety, feasibility, and effect of exercise in women with stage II+ breast cancer. Arch Phys Med Rehabil. 2018;99:2621–36. (PMID: 2973031910.1016/j.apmr.2018.03.026)
Ehlers DK, DuBois K, Salerno EA. The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review. Expert Rev Anticancer Ther. 2020;20. Epub ahead of print 2020. https://doi.org/10.1080/14737140.2020.1813028 .
Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32:335–46. (PMID: 2434421810.1200/JCO.2013.49.5523)
Baguley B, Bolam K, Wright O, et al. The effect of nutrition therapy and exercise on cancer-related fatigue and quality of life in men with prostate cancer: a systematic review. Nutrients. 2017;9:1003. (PMID: 28895922562276310.3390/nu9091003)
Singh B, Hayes SC, Spence RR, et al. Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness. Int J Behav Nutr Phys Act. 2020;17:122. (PMID: 32972439751329110.1186/s12966-020-01021-7)
Vermaete N, Wolter P, Verhoef G, et al. Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol. 2013;92:1007–21. (PMID: 2340809610.1007/s00277-013-1689-1)
Bergenthal N, Will A, Streckmann F, et al. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev. 2014. Epub ahead of print 11 November 2014. https://doi.org/10.1002/14651858.CD009075.PUB2 .
Physical Activity Guidelines for Americans | health.gov, https://health.gov/our-work/nutrition-physical-activity/physical-activity-guidelines . Accessed 15 October 2023.
Brown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomark Prev. 2011;20:123–33. (PMID: 10.1158/1055-9965.EPI-10-0988)
Gong S, Sheng P, Jin H, et al. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. Plos One. 2014;9. Epub ahead of print 8 January 2014. https://doi.org/10.1371/JOURNAL.PONE.0084391 .
Paulsen Ø, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32:3221–8. (PMID: 2500273110.1200/JCO.2013.54.3926)
Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31:3076–82. (PMID: 2389797010.1200/JCO.2012.44.4661)
Oh HJ, Yoon BH, Ha YC, et al. The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis. Osteoporos Int. 2020;31:267–75. (PMID: 3177663610.1007/s00198-019-05220-2)
Shahraki MS, Mahmoudieh M, Kalidari B, et al. Bone health after bariatric surgery: consequences, prevention, and treatment. Adv Biomed Res. 2022;11:92. (PMID: 10.4103/abr.abr_182_21)
Shin DW, Suh B, Suh B, et al. Increased risk of osteoporotic fracture in postgastrectomy gastric cancer survivors compared with matched controls: a nationwide cohort study in Korea. Am J Gastroenterol. 2019;114:1735–43. (PMID: 3165812210.14309/ajg.0000000000000436)
Muszyński T, Polak K, Fratczaką A, et al. Vitamin D—The nutritional status of post-gastrectomy gastric cancer patients—systematic review. Nutrients. 2022;14. Epub ahead of print 1 July 2022. https://doi.org/10.3390/NU14132712 .
Climent M, Pera M, Aymar I, et al. Bone health in long-term gastric cancer survivors: a prospective study of high-dose vitamin D supplementation using an easy administration scheme. J Bone Miner Metab. 2018;36:462–9. (PMID: 2876613410.1007/s00774-017-0856-1)
Mott A, Bradley T, Wright K, et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int. 2019;30:1543–59. (PMID: 3107681710.1007/s00198-019-04949-0)
Farsinejad-Marj M, Saneei P, Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016;27:1389–99. (PMID: 2655674210.1007/s00198-015-3400-y)
Davis JL, Ripley RT. Postgastrectomy syndromes and nutritional considerations following gastric surgery. Surg Clin North Am. 2017;97:277–93. (PMID: 2832518710.1016/j.suc.2016.11.005)
Cai Z, Zhou Y, Wang C, et al. Optimal reconstruction methods after distal gastrectomy for gastric cancer: a systematic review and network meta-analysis. Medicine (United States). 2018;97. Epub ahead of print 1 May 2018. https://doi.org/10.1097/MD.0000000000010823 .
Enani G, Bilgic E, Lebedeva E, et al. The incidence of iron deficiency anemia post-Roux-en-Y gastric bypass and sleeve gastrectomy: a systematic review. Surg Endosc. 2020;34:3002–10. (PMID: 3148592810.1007/s00464-019-07092-3)
Lim C-H, Kim SW, Kim WC, et al. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. World J Gastroenterol. 2012;18:6114–9. (PMID: 23155340349688810.3748/wjg.v18.i42.6114)
Mukoyama T, Kanaji S, Sawada R, et al. Assessment of risk factors for delayed gastric emptying after distal gastrectomy for gastric cancer. Sci Rep. 2022;12:15903. (PMID: 36151365950816010.1038/s41598-022-20151-5)
Yang J-Y, Lee H-J, Alzahrani F, et al. Postprandial changes in gastrointestinal hormones and hemodynamics after gastrectomy in terms of early dumping syndrome. J Gastric Cancer. 2020;20:256–66. (PMID: 33024582752198610.5230/jgc.2020.20.e24)
Blouhos K, Boulas KA, Tsalis K, et al. Management of afferent loop obstruction: reoperation or endoscopic and percutaneous interventions? World J Gastrointest Surg. 2015;7:190–5. (PMID: 26425267458223610.4240/wjgs.v7.i9.190)
Termsinsuk P, Chantarojanasiri T, Pausawasdi N. Diagnosis and treatment of the afferent loop syndrome. Clin J Gastroenterol. 2020;13:660–8. (PMID: 3263823010.1007/s12328-020-01170-z)
Chen G, Yu Z, Zhang Y, et al. Radiation-induced gastric injury during radiotherapy: molecular mechanisms and clinical treatment. J Radiat Res. 2023;1–10.
Shadad AK, Sullivan FJ, Martin JD, et al. Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol: WJG. 2013;19:185–98. (PMID: 23345941354756010.3748/wjg.v19.i2.185)
Hu Y, Vos EL, Baser RE, et al. longitudinal analysis of quality-of-life recovery after gastrectomy for cancer. Ann Surg Oncol. 2021;28:48–56. (PMID: 3312556910.1245/s10434-020-09274-z)
Karanicolas PJ, Graham D, Gönen M, et al. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg. 2013;257:1039–46. (PMID: 2366597010.1097/SLA.0b013e31828c4a19)
Brenkman HJF, Tegels JJW, Ruurda JP, et al. Factors influencing health-related quality of life after gastrectomy for cancer. Gastric Cancer. 2018;21:524–32. (PMID: 2906759710.1007/s10120-017-0771-0)
Akkerman RDL, Haverkamp L, van Rossum PSN, et al. Long-term quality of life after oesophagectomy with gastric conduit interposition for cancer. Eur J Cancer. 2015;51:1538–45. (PMID: 2603155210.1016/j.ejca.2015.05.006)
Arndt V, Merx H, Stürmer T, et al. Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer. 2004;40:673–80. (PMID: 1501006710.1016/j.ejca.2003.12.007)
Choi J, Kim S, Choi M, et al. Factors affecting the quality of life of gastric cancer survivors. Support Care Cancer. 2022;30:3215–24. (PMID: 34973098885715310.1007/s00520-021-06683-y)
Kim GM, Kim SJ, Song SK, et al. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. BMC Cancer. 2017;17. Epub ahead of print 20 April 2017. https://doi.org/10.1186/S12885-017-3260-2 .
Han L. Prevalence, risk factors and prognostic role of anxiety and depression in surgical gastric cancer patients. Transl Cancer Res. 2020;9:1371. (PMID: 35117485879798810.21037/tcr.2020.01.11)
Han KH, Hwang IC, Kim S, et al. Factors associated with depression in disease-free stomach cancer survivors. J Pain Symptom Manage. 2013;46:511–22. (PMID: 2348982910.1016/j.jpainsymman.2012.10.234)
Zhang J kui, Fang L li, Zhang D wei, et al. Type D personality in gastric cancer survivors: association with poor quality of life, overall survival, and mental health. J Pain Symptom Manage. 2016;52:81–91.
Kim M, Choi KS, Suh M, et al. Risky lifestyle behaviors among gastric cancer survivors compared with matched non-cancer controls: results from baseline result of community based cohort study. Cancer Res Treat. 2018;50:738–47. (PMID: 2874503710.4143/crt.2017.129)
Han CJ, Tounkara F, Kalady M, et al. Risk factors of health-related quality of life among gastrointestinal cancer survivors in the U.S.: with a focus on social and behavioral determinants of health (SBDH). Int J Environ Res Public Health. 2023;20:6676.
Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. https://doi.org/10.1245/s10434-0 .
Pinheiro LC, Wheeler SB, Chen RC, et al. The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. Cancer. 2015;121:1312–20. (PMID: 2552269210.1002/cncr.29205)
Hamakawa T, Kurokawa Y, Mikami J, et al. Risk factors for postoperative complications after gastrectomy in gastric cancer patients with comorbidities. Surg Today. 2016;46:224–8. (PMID: 2591119010.1007/s00595-015-1175-6)
Bevers TB, Niell BL, Helvie M, et al. NCCN Guidelines Version 2.2023 Breast Cancer Screening and Diagnosis Continue NCCN Guidelines Panel Disclosures. 2023. https://www.nccn.org/home/member ..
Ness RM, Llor X, Chair V, et al. NCCN Guidelines Version 1.2023 Colorectal Cancer Screening Continue NCCN Guidelines Panel Disclosures. 2023. https://www.nccn.org/home/member .
Wood DE, Kazerooni EA, Chair ф V, et al. NCCN Guidelines Version 1.2024 Lung Cancer Screening Continue NCCN Guidelines Panel Disclosures. 2023. http://www.shouldiscreen.com/benefits-and-harms-screening .
Partridge EE, Campos SM, Farmer M, et al. NCCN Guidelines index cervical cancer screening toc discussion continue * nccn guidelines panel disclosures nccn guidelines version 2.2012 Panel Members Cervical Cancer Screening. 2012.
Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol. 2015;7:455. (PMID: 26690981467839210.4251/wjgo.v7.i12.455)
Li S, Zhao W, Xia L, et al. How long will it take to launch an effective Helicobacter pylori vaccine for humans? Infect Drug Resist. 2023;16:3787. (PMID: 373424351027864910.2147/IDR.S412361)
Ward EM, Flowers CR, Gansler T, et al. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin. 2017;67:398–410. (PMID: 2875324110.3322/caac.21407)
Lee JE, Shin DW, Lee H, et al. One-year experience managing a cancer survivorship clinic using a shared-care model for gastric cancer survivors in Korea. J Korean Med Sci. 2016;31:859. (PMID: 27247493485366310.3346/jkms.2016.31.6.859)
Sitte J, Frentiu E, Baumann C, et al. Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: a prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2019;49:84–90. (PMID: 3048546710.1111/apt.15057)
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–99.
Cancer: What do the codes in the doctor’s letter mean? 2016. https://www.ncbi.nlm.nih.gov/books/NBK279426/ . Accessed on 8 Oct 2023.

Keywords: Alcohol cessation; Gastric cancer; Modifiable risk factors; Quality of life; Smoking cessation; Survivorship; Toxicity

Date Created: 20240105 Date Completed: 20240619 Latest Revision: 20240619

20240619

10.1007/s12029-023-01001-7

38180678